Month: January 2024

Treatment with glatiramer acetate in APPswe/PS1dE9 mice at an early stage of Alzheimer’s disease prior to amyloid-beta deposition delays the disease’s pathological development and ameliorates cognitive decline

BackgroundAlzheimer’s disease (AD) is characterized by neuroinflammation, which is frequently accompanied by immune system dysfunction. Although the mechanism of neurodegenerative lesions is unclear, various clinical trials have highlighted that early intervention in AD is crucial to the success of treatment. In order to explore the potential of immunotherapy in the early period of AD, the […]

Published on January 30, 2024

Oscillatory characteristics of resting-state magnetoencephalography reflect pathological and symptomatic conditions of cognitive impairment

BackgroundDementia and mild cognitive impairment are characterised by symptoms of cognitive decline, which are typically assessed using neuropsychological assessments (NPAs), such as the Mini-Mental State Examination (MMSE) and Frontal Assessment Battery (FAB). Magnetoencephalography (MEG) is a novel clinical assessment technique that measures brain activities (summarised as oscillatory parameters), which are associated with symptoms of cognitive […]

Published on January 30, 2024

Study Confirms Smokers at Higher Risk for ALS

New research is helping confirm smoking as a risk factor for the devastating brain illness amyotrophic lateral sclerosis (ALS). ALS affects roughly 31,000 Americans each year, with about 5,000 new cases diagnosed annually, according to the U.S. Centers for Disease Control… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a […]

Published on January 30, 2024